CN101247827B - 疫苗生产方法 - Google Patents

疫苗生产方法 Download PDF

Info

Publication number
CN101247827B
CN101247827B CN2006800311786A CN200680031178A CN101247827B CN 101247827 B CN101247827 B CN 101247827B CN 2006800311786 A CN2006800311786 A CN 2006800311786A CN 200680031178 A CN200680031178 A CN 200680031178A CN 101247827 B CN101247827 B CN 101247827B
Authority
CN
China
Prior art keywords
sugar
minutes
hours
amino
carbodiimide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2006800311786A
Other languages
English (en)
Chinese (zh)
Other versions
CN101247827A (zh
Inventor
R·L·比曼斯
P·迪维维耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0513071.1A external-priority patent/GB0513071D0/en
Priority claimed from GB0515556A external-priority patent/GB0515556D0/en
Priority claimed from GB0524204A external-priority patent/GB0524204D0/en
Priority claimed from GB0526040A external-priority patent/GB0526040D0/en
Priority claimed from GB0526041A external-priority patent/GB0526041D0/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority claimed from PCT/EP2006/006270 external-priority patent/WO2007000343A2/en
Publication of CN101247827A publication Critical patent/CN101247827A/zh
Application granted granted Critical
Publication of CN101247827B publication Critical patent/CN101247827B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN2006800311786A 2005-06-27 2006-06-23 疫苗生产方法 Active CN101247827B (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GB0513069.5 2005-06-27
GBGB0513071.1A GB0513071D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GB0513071.1 2005-06-27
GBGB0513069.5A GB0513069D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GB0515556A GB0515556D0 (en) 2005-07-28 2005-07-28 Immunogenic composition
GB0515556.9 2005-07-28
GB0524204A GB0524204D0 (en) 2005-11-28 2005-11-28 Immunogenic composition
GB0524204.5 2005-11-28
GB0526041.9 2005-12-21
GB0526040.1 2005-12-21
GB0526040A GB0526040D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
GB0526041A GB0526041D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
PCT/EP2006/006270 WO2007000343A2 (en) 2005-06-27 2006-06-23 Process for manufacturing vaccines

Publications (2)

Publication Number Publication Date
CN101247827A CN101247827A (zh) 2008-08-20
CN101247827B true CN101247827B (zh) 2013-07-17

Family

ID=34856207

Family Applications (4)

Application Number Title Priority Date Filing Date
CN2006800311786A Active CN101247827B (zh) 2005-06-27 2006-06-23 疫苗生产方法
CN2006800233344A Active CN101208103B (zh) 2005-06-27 2006-06-23 免疫原性组合物
CN2006800230577A Active CN101208101B (zh) 2005-06-27 2006-06-23 免疫原性组合物
CN200680023149.5A Active CN101222935B (zh) 2005-06-27 2006-06-23 免疫原性组合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN2006800233344A Active CN101208103B (zh) 2005-06-27 2006-06-23 免疫原性组合物
CN2006800230577A Active CN101208101B (zh) 2005-06-27 2006-06-23 免疫原性组合物
CN200680023149.5A Active CN101222935B (zh) 2005-06-27 2006-06-23 免疫原性组合物

Country Status (8)

Country Link
CN (4) CN101247827B (https=)
BE (1) BE2021C560I2 (https=)
ES (1) ES2367918T5 (https=)
FR (1) FR12C0060I2 (https=)
GB (1) GB0513069D0 (https=)
NO (2) NO2021022I1 (https=)
UA (1) UA97233C2 (https=)
ZA (3) ZA200710853B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX354103B (es) * 2012-01-30 2018-02-13 Serum Inst India Ltd Composicion inmunogenica.
DK2885007T3 (en) * 2012-08-16 2018-12-03 Pfizer Methods for glycoconjugation and compositions
BR112019003992A2 (pt) * 2016-09-02 2019-05-28 Sanofi Pasteur Inc vacina contra neisseria meningitidis
SI3544637T1 (sl) * 2016-11-25 2021-02-26 Glaxosmithkline Biologicals S.A. Nativni OMV-antigen konjugati in njihova uporaba
CN109879967A (zh) * 2017-12-15 2019-06-14 苏州和锐生物科技有限公司 一种乙酰氨基葡萄糖偶联物的制备方法及应用
CN110251667A (zh) * 2018-05-11 2019-09-20 武汉博沃生物科技有限公司 一种免疫组合制剂及其制备方法和应用
US12533418B2 (en) * 2019-11-22 2026-01-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
CN115819616B (zh) * 2021-07-28 2025-04-11 江苏瑞科生物技术股份有限公司 一种基因重组vzv融合蛋白及其制备方法和应用
CN115721709A (zh) * 2021-08-27 2023-03-03 康希诺生物股份公司 一种肺炎球菌结合疫苗制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180815A (en) * 1988-04-13 1993-01-19 Fuji Photo Film Co., Ltd. Modified protein for carrying hapten
CN1558773A (zh) * 2001-04-06 2004-12-29 巴斯德研究院 由与破伤风类毒素结合的霍乱弧菌o139的脂多糖的多糖部分组成的缀合疫苗

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20024224A3 (cs) * 2000-06-29 2003-05-14 Glaxosmithkline Biologicals S. A. Farmaceutický prostředek
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CN1401328A (zh) * 2002-10-18 2003-03-12 北京绿竹生物技术有限责任公司 流行性脑脊髓膜炎多糖－蛋白结合疫苗
EP2172213B1 (en) * 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180815A (en) * 1988-04-13 1993-01-19 Fuji Photo Film Co., Ltd. Modified protein for carrying hapten
CN1558773A (zh) * 2001-04-06 2004-12-29 巴斯德研究院 由与破伤风类毒素结合的霍乱弧菌o139的脂多糖的多糖部分组成的缀合疫苗

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
G. Ada and D. Isaacs.Carbohydrate–protein conjugate vaccines.《Clinical Microbiology and Infection》.2003,第9卷(第2期),79-85. *
刘保奎等.多糖蛋白结合疫苗.《中国计划免疫》.1999,第5卷(第2期),114-118. *

Also Published As

Publication number Publication date
CN101247827A (zh) 2008-08-20
CN101208101A (zh) 2008-06-25
ES2367918T3 (es) 2011-11-10
FR12C0060I1 (https=) 2012-12-14
ZA200711074B (en) 2009-07-29
BE2021C560I2 (https=) 2026-02-02
NO2025018I1 (no) 2025-04-08
CN101222935A (zh) 2008-07-16
CN101208103A (zh) 2008-06-25
CN101208103B (zh) 2013-04-24
FR12C0060I2 (fr) 2017-01-06
GB0513069D0 (en) 2005-08-03
ZA200710853B (en) 2009-04-29
ES2367918T5 (es) 2014-11-21
ZA200710909B (en) 2009-04-29
CN101222935B (zh) 2015-07-29
UA97233C2 (uk) 2012-01-25
CN101208101B (zh) 2013-01-02
NO2021022I1 (no) 2021-05-25

Similar Documents

Publication Publication Date Title
KR101408113B1 (ko) 백신 제조 방법
CN110859957B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
JP2010514818A (ja) ワクチン
CN101247827B (zh) 疫苗生产方法
HK1114011B (en) Process for manufacturing vaccines
HK1114011C (en) Process for manufacturing vaccines
HK1153679A (en) Process for manufacturing vaccines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant